A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Alpha Teknova, Inc. (referred to herein as the Company, Teknova, we, us or our) is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Our more than 3,000 customers span the continuum of the life sciences market and include leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Our Company is built around our knowledge, methods, and know-how in our manufacturing processes and infrastructure, which are highly adaptable and configurable. These proprietary processes enable us to manufacture and deliver high-quality, custom, made-to-order products with short turnaround times and at scale, across all stages of our customers’ product development, including commercialization.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 41M | 41M | 38M | 37M | 41M | 37M |
| Net Income | -17M | -17M | -27M | -37M | -47M | -9.8M |
| EPS | $-0.32 | $-0.32 | $-0.57 | $-1.16 | $-1.69 | $-0.61 |
| Free Cash Flow | -9.8M | -9.8M | -14M | -27M | -56M | -29M |
| ROIC | -17.6% | -21.1% | -29.1% | -35.6% | -39.0% | -6.3% |
| Gross Margin | 33.2% | 33.2% | 19.2% | 28.1% | 42.2% | 47.8% |
| Debt/Equity | 0.19 | 0.19 | 0.21 | 0.15 | 0.22 | 0.08 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -17M | -17M | -26M | -36M | -50M | -12M |
| Operating Margin | -41.9% | -41.9% | -69.3% | -96.9% | -119.9% | -32.5% |
| ROE | -25.1% | -22.8% | -32.5% | -40.9% | -47.5% | -6.8% |
| Shares Outstanding | 54M | 54M | 47M | 32M | 28M | 16M |
| Metric | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 31M | 37M | 41M | 37M | 38M | 41M | 41M |
| Gross Margin | 56.7% | 47.8% | 42.2% | 28.1% | 19.2% | 33.2% | 33.2% |
| R&D | 1.5M | 4.3M | 7.7M | 5.6M | 2.8M | 2.2M | 2.2M |
| SG&A | 8.2M | 20M | 28M | 25M | 23M | 20M | 20M |
| EBIT | 4.7M | -12M | -50M | -36M | -26M | -17M | -17M |
| Op. Margin | 14.9% | -32.5% | -119.9% | -96.9% | -69.3% | -41.9% | -41.9% |
| Net Income | 608K | -9.8M | -47M | -37M | -27M | -17M | -17M |
| Net Margin | 1.9% | -26.6% | -114.6% | -100.3% | -70.9% | -42.6% | -42.6% |
| Non-Recurring | 0 | 0 | 17M | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | 30.3% | -6.3% | -39.0% | -35.6% | -29.1% | -21.1% | -17.6% |
| ROE | 3.6% | -6.8% | -47.5% | -40.9% | -32.5% | -22.8% | -25.1% |
| ROA | 1.0% | -5.9% | -31.2% | -28.6% | -22.5% | -15.5% | -16.7% |
| Cash Flow | |||||||
| Op. Cash Flow | 2.5M | -9.1M | -27M | -19M | -12M | -8.6M | -8.6M |
| Free Cash Flow | -3.0M | -29M | -56M | -27M | -14M | -9.8M | -9.8M |
| Owner Earnings | 161K | -14M | -34M | -29M | -23M | -18M | -18M |
| CapEx | 5.5M | 20M | 28M | 7.9M | 1.1M | 1.1M | 1.1M |
| Maint. CapEx | 2.0M | 2.9M | 3.2M | 5.7M | 6.6M | 6.3M | 6.3M |
| Growth CapEx | 3.4M | 17M | 25M | 2.3M | 0 | 0 | 0 |
| D&A | 2.0M | 2.9M | 3.2M | 5.7M | 6.6M | 6.3M | 6.3M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 300K | 1.6M | 3.7M | 4.1M | 3.7M | 3.4M | 3.4M |
| Debt Repayment | 45K | 153K | 0 | 10M | 25K | 100K | 100K |
| Balance Sheet | |||||||
| Net Debt | -5.1M | -76M | -62M | -15M | -13M | -8.2M | 7.2M |
| Cash & Equiv. | 3.3M | 88M | 42M | 28M | 3.7M | 5.9M | 5.9M |
| Long-Term Debt | 0 | 12M | 22M | 13M | 9.4M | 13M | 13M |
| Debt/Equity | 0.00 | 0.08 | 0.22 | 0.15 | 0.21 | 0.19 | 0.19 |
| Interest Coverage | 129.5 | -29.0 | N/A | -43.2 | -16.8 | -11.6 | -11.6 |
| Equity | 17M | 143M | 100M | 90M | 82M | 69M | 69M |
| Total Assets | 63M | 167M | 152M | 129M | 119M | 104M | 104M |
| Total Liabilities | 11M | 23M | 52M | 39M | 36M | 35M | 35M |
| Intangibles | 36M | 35M | 35M | 28M | 26M | 24M | 24M |
| Retained Earnings | 2.3M | -7.5M | -55M | -92M | -119M | -136M | -136M |
| Working Capital | 12M | 93M | 50M | 37M | 32M | 27M | 27M |
| Current Assets | 16M | 101M | 61M | 46M | 43M | 35M | 35M |
| Current Liabilities | 4.0M | 7.7M | 11M | 8.9M | 11M | 7.5M | 7.5M |
| Per Share Data | |||||||
| EPS | 0.16 | -0.61 | -1.69 | -1.16 | -0.57 | -0.32 | -0.32 |
| Owner EPS | 0.01 | -0.84 | -1.22 | -0.90 | -0.48 | -0.34 | -0.34 |
| Book Value | 0.60 | 8.91 | 3.56 | 2.84 | 1.76 | 1.28 | 1.28 |
| Cash Flow/Share | 0.09 | -0.56 | -0.98 | -0.59 | -0.26 | -0.16 | -0.20 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 28.0M | 16.1M | 28.1M | 31.7M | 46.9M | 53.9M | 53.9M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -9.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 2.2 | 1.5 | 1.3 | 5.0 | 3.2 | 2.4 |
| Price/Sales | N/A | 9.6 | 6.3 | 2.8 | 4.8 | 7.6 | 4.0 |
| FCF Yield | N/A | -9.0% | -38.3% | -22.7% | -3.3% | -4.5% | -6.0% |
| Market Cap | N/A | 320M | 145M | 118M | 410M | 218M | 163M |
| Avg. Price | N/A | 21.94 | 9.24 | 3.21 | 3.89 | 5.73 | 3.03 |
| Year-End Price | N/A | 19.92 | 5.17 | 3.72 | 8.73 | 4.04 | 3.03 |
Alpha Teknova, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 34.1%.
Alpha Teknova, Inc. (TKNO) has a 5-year average return on invested capital (ROIC) of -26.2%. This is below average and may indicate limited pricing power.
Alpha Teknova, Inc. (TKNO) has a market capitalization of $163M. It is classified as a small-cap stock.
Alpha Teknova, Inc. (TKNO) does not currently pay a regular dividend.
Alpha Teknova, Inc. (TKNO) operates in the In Vitro & In Vivo Diagnostic Substances industry, within the Healthcare sector.
Alpha Teknova, Inc. (TKNO) reported annual revenue of $41 million in its most recent fiscal year, based on SEC EDGAR filings.
Alpha Teknova, Inc. (TKNO) has a net profit margin of -42.6%. The company is currently unprofitable.
Alpha Teknova, Inc. (TKNO) generated $-10 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Alpha Teknova, Inc. (TKNO) has a debt-to-equity ratio of 0.19. This indicates a conservatively financed balance sheet.
Alpha Teknova, Inc. (TKNO) reported earnings per share (EPS) of $-0.32 in its most recent fiscal year.
Alpha Teknova, Inc. (TKNO) has a return on equity (ROE) of -22.8%. A negative ROE may indicate losses or negative equity.
Alpha Teknova, Inc. (TKNO) has a 5-year average gross margin of 34.1%. This indicates decent pricing power.
The Ledger Terminal provides 6 years of financial data for Alpha Teknova, Inc. (TKNO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Alpha Teknova, Inc. (TKNO) has a book value per share of $1.28, based on its most recent annual SEC filing.
No recent press releases.